OncoMatch/Clinical Trials/NCT05943067
CD45RA Depleted DLI After TCRα/β Depleted Haploidentical HCT
Is NCT05943067 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies CD45RA depleted donor lymphocyte infusion (DLI) for hematologic malignancy.
Treatment: CD45RA depleted donor lymphocyte infusion (DLI) — The purpose of this clinical trial is to examine safety and toxicity of CD45RA depleted donor lymphocyte infusion (DLI) after transplantation of TCRα/β/CD19 depleted peripheral blood stem cells.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Prior therapy
Must have received: hematopoietic cell transplantation
prior hematopoietic cell transplantation (HCT)
Cannot have received: T-cell or Interleukin-2 (IL-2) targeted medication (alemtuzumab, basiliximab)
Treatment with T-cell or Interleukin-2 (IL-2) targeted medication (e.g. alemtuzumab, basiliximab) within 60 days prior to study product infusion
Cannot have received: prednisolone >2 mg/kg/day (or equivalent glucocorticosteroids)
Treatment with prednisolone at >2 mg/kg/day (or equivalent dosing of alternative glucocorticosteroids) at time of study product infusion.
Cannot have received: investigational drug
Treatment with another investigational drug within one month before inclusion
Lab requirements
Kidney function
creatinine clearance above threshold defined for stem cell transplantation according to local clinical standard
Liver function
bilirubin ≤2 mg/dL and transaminases ≤400 U/L
Cardiac function
ejection fraction ≥40% or shortening fraction ≥20% on echocardiography; ≤ grade II hypertension by Common Toxicity Criteria (CTC)
Liver function abnormalities with bilirubin >2 mg/dL and elevation of transaminases higher than 400 U/L [excluded]; Creatinine clearance below threshold defined for stem cell transplantation according to local clinical standard [excluded]; Ejection fraction <40% or Shortening fraction <20% on echocardiography. Patients with > grade II hypertension by Common Toxicity Criteria (CTC) [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify